Anavex Appoints Wolfgang Liedtke as Senior VP, Global Head of Neurology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Anavex Life Sciences (AVXL) announced the appointment of Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology. Liedtke is a board-certified neurologist, who brings more than 25 years of extensive experience in developing and delivering innovative medicines in a broad range of CNS diseases, including genetic medicines and global therapeutic development. Most recently he was Chair of Neurology at Regeneron (REGN).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVXL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVXL
Wall Street analysts forecast AVXL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVXL is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 5.050
Low
20.00
Averages
20.00
High
20.00
Current: 5.050
Low
20.00
Averages
20.00
High
20.00
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Danaher Exceeds Q4 Earnings Guidance but Faces Market Skepticism
- Revenue Growth: Danaher's Q4 2025 revenue rose 4.6% year-over-year to $6.84 billion, surpassing the analyst consensus estimate of $6.81 billion, indicating strong performance in the medical equipment sector.
- Adjusted EPS: Adjusted earnings per share increased by 4.2% to $2.23, exceeding the market expectation of $2.15, reflecting the company's ongoing improvement in profitability.
- Cautious Market Outlook: Despite better-than-expected core revenue growth guidance, management's outlook for 2026 remains conservative, anticipating core revenue growth between 3% and 6%, highlighting uncertainty in market demand.
- Bioprocessing Recovery: The bioprocessing segment saw core revenue growth of 8%, driven by strong demand for consumables, indicating a strengthening recovery in this key market.
Continue Reading
Anavex Joins ACCESS-AD Initiative to Accelerate Alzheimer's Disease Treatment Adoption
- Industry Partnership: Anavex Life Sciences participates as a key industry partner in the ACCESS-AD initiative, funded by the European Commission's Innovative Health Initiative, aimed at accelerating the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease, which is expected to significantly enhance patient treatment experiences.
- Clinical Research Integration: Within this initiative, Anavex's investigational small-molecule therapy blarcamesine will be evaluated in a clinical prediction study, designed to restore cellular function by activating SIGMAR1, thereby providing personalized treatment options for Alzheimer's patients.
- Multimodal Clinical Framework: ACCESS-AD establishes a coordinated multimodal clinical framework that integrates advanced neuroimaging, blood-based biomarkers, and AI-driven decision support, aimed at optimizing patient pathways and enhancing early detection and safe implementation of emerging therapies.
- Commitment to Precision Medicine: Anavex emphasizes its long-standing commitment to precision medicine by integrating clinical data and digital tools to explore how molecular-targeted therapies can complement the Alzheimer's treatment ecosystem, addressing the growing patient needs.
Continue Reading